DR. SETH BAUM SHARES IMPORTANT NEWS FOR CARDIAC PATIENTS
In the U.S. someone has a heart attack or stroke every 40 seconds,1 and nearly one in three of these patients will have another cardiovascular (CV) event.
Seth J. Baum, M.D., will be at the American College of Cardiology’s (ACC) 67th Annual Scientific Sessions to discuss new research that explores the clinical impact for cardiovascular patients denied access to PCSK9 inhibitors. He will also touch on the significant need to ensure high-risk patients – people with high ‘bad’ cholesterol and those at risk for a cardiovascular event – who may benefit from a PCSK9 inhibitor can receive it if appropriately prescribed by their physicians. Many patients with established CV disease cannot access PCSK9 inhibitors because of excessive “red tape” generated by restrictive insurance paperwork.
Related links: Amgen